http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 08 Jun 2026 14:01:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++25-NSE+++++IO+Biotech%2C+Inc.+++++++++++++++++++++++Filed+by%3A+Nasdaq+Stock+Market+LLC/26616571.html si-local-file:///var/storage/secattach/20260608/26616571.html http://www.streetinsider.com/SEC+Filings/Form++25-NSE+++++IO+Biotech%2C+Inc.+++++++++++++++++++++++Filed+by%3A+Nasdaq+Stock+Market+LLC/26616571.html Mon, 08 Jun 2026 14:01:00 -0400 IOBTQ O.53121624 http://www.streetinsider.com/SEC+Filings/Form++25-NSE+++++IO+Biotech%2C+Inc.+++++++++++++++++++++++Filed+by%3A+Nasdaq+Stock+Market+LLC/26616571.html si-local-file:///var/storage/secattach/20260608/26616571.html http://www.streetinsider.com/SEC+Filings/Form++25-NSE+++++IO+Biotech%2C+Inc.+++++++++++++++++++++++Filed+by%3A+Nasdaq+Stock+Market+LLC/26616571.html Mon, 08 Jun 2026 14:01:00 -0400 IOBTQ O.53121624 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++IO+Biotech%2C+Inc.+++++++++++++++++++++++Filed+by%3A+Lundbeckfond+Invest+AS/26591644.html si-local-file:///var/storage/secattach/20260602/26591644.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++IO+Biotech%2C+Inc.+++++++++++++++++++++++Filed+by%3A+Lundbeckfond+Invest+AS/26591644.html Tue, 02 Jun 2026 16:07:00 -0400 IOBTQ O.53121624 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++IO+Biotech%2C+Inc.+++++++++++++++++++++++Filed+by%3A+Lundbeckfond+Invest+AS/26591644.html si-local-file:///var/storage/secattach/20260602/26591644.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++IO+Biotech%2C+Inc.+++++++++++++++++++++++Filed+by%3A+Lundbeckfond+Invest+AS/26591644.html Tue, 02 Jun 2026 16:07:00 -0400 IOBTQ O.53121624 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++IO+Biotech%2C+Inc.+++++++++++++++++++++++Filed+by%3A+Chernett+Jorey/26529697.html si-local-file:///var/storage/secattach/20260520/26529697.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++IO+Biotech%2C+Inc.+++++++++++++++++++++++Filed+by%3A+Chernett+Jorey/26529697.html Wed, 20 May 2026 17:43:00 -0400 IOBTQ O.53121624 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++IO+Biotech%2C+Inc.+++++++++++++++++++++++Filed+by%3A+Chernett+Jorey/26529697.html si-local-file:///var/storage/secattach/20260520/26529697.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++IO+Biotech%2C+Inc.+++++++++++++++++++++++Filed+by%3A+Chernett+Jorey/26529697.html Wed, 20 May 2026 17:43:00 -0400 IOBTQ O.53121624 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++IO+Biotech%2C+Inc.+++++++++++++++++++++++Filed+by%3A+Point72+Asset+Management%2C+L.P./26506944.html si-local-file:///var/storage/secattach/20260515/26506944.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++IO+Biotech%2C+Inc.+++++++++++++++++++++++Filed+by%3A+Point72+Asset+Management%2C+L.P./26506944.html Fri, 15 May 2026 16:42:00 -0400 IOBTQ O.53121624 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++IO+Biotech%2C+Inc.+++++++++++++++++++++++Filed+by%3A+Point72+Asset+Management%2C+L.P./26506944.html si-local-file:///var/storage/secattach/20260515/26506944.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++IO+Biotech%2C+Inc.+++++++++++++++++++++++Filed+by%3A+Point72+Asset+Management%2C+L.P./26506944.html Fri, 15 May 2026 16:42:00 -0400 IOBTQ O.53121624 http://www.streetinsider.com/Press+Releases/Advancing+Drug+Pipelines+Drive+Biotech+Valuations+as+Scientific+Progress+Gains+Financial+Recognition/26347871.html <p>AUSTIN, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=fhktGMAc-YB8CA0Ov1Oayzf1xhnRI1_P2ocPmQDq0oZMFZs93VPW-0nX2AoZLMxpNsmGfNCCdHob5lRV2LFvT4_ZFAZd0THf1smoaVoIk6BRW86-qLxyaiHY_UvEA2--LWapUn5t-yI-Ujbf5eg3164eycLOmtE6il6mBvSmBjS2EAIxD0Rs8pPaV9FgoYe9IqNUeL0pAWfWEd5oFEk37InMLSR3xVidVCSAxDP9NNZ3Z-QsI5fVGiPPLFS1Kq_Vt_3IdFk9d3l50ZqYbIl6M-Ow5fNp_I9a-5QjUO6zhSaAZS55PJX9EodGQzpOehfq" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The biotechnology industry is experiencing a subtle yet meaningful transformation that is redefining how value is interpreted within a sector long associated with extended development cycles and inherent uncertainty. As therapeutic candidates advance toward commercialization, scientific achievement is no longer viewed purely as an expense tied to research and development but rather as something that can be quantified as a financial asset. This transition is <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Tj_59AWfKmWrcNIjgKv_IcQvml_wBRJCLCVZDxC-TidBIS-ypgAR7D3--3meCxuE34GXA30-avCMdLDXJSHg-g==" rel="nofollow" target="_blank">supported</a> by fair-value accounting principles under U.S. GAAP, which enable life sciences companies to http://www.streetinsider.com/Press+Releases/Advancing+Drug+Pipelines+Drive+Biotech+Valuations+as+Scientific+Progress+Gains+Financial+Recognition/26347871.html Wed, 22 Apr 2026 08:30:00 -0400 A.06822034 A.27822871 A.31293549 A.60012005 AUTL IOBTQ O.00222322 O.00573636 O.01670430 O.04698756 O.20026344 O.37399203 O.37872132 O.46180359 O.53121624 OTLC RHHBY RO WVE http://www.streetinsider.com/Press+Releases/Advancing+Drug+Pipelines+Drive+Biotech+Valuations+as+Scientific+Progress+Gains+Financial+Recognition/26347871.html <p>AUSTIN, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=fhktGMAc-YB8CA0Ov1Oayzf1xhnRI1_P2ocPmQDq0oZMFZs93VPW-0nX2AoZLMxpNsmGfNCCdHob5lRV2LFvT4_ZFAZd0THf1smoaVoIk6BRW86-qLxyaiHY_UvEA2--LWapUn5t-yI-Ujbf5eg3164eycLOmtE6il6mBvSmBjS2EAIxD0Rs8pPaV9FgoYe9IqNUeL0pAWfWEd5oFEk37InMLSR3xVidVCSAxDP9NNZ3Z-QsI5fVGiPPLFS1Kq_Vt_3IdFk9d3l50ZqYbIl6M-Ow5fNp_I9a-5QjUO6zhSaAZS55PJX9EodGQzpOehfq" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The biotechnology industry is experiencing a subtle yet meaningful transformation that is redefining how value is interpreted within a sector long associated with extended development cycles and inherent uncertainty. As therapeutic candidates advance toward commercialization, scientific achievement is no longer viewed purely as an expense tied to research and development but rather as something that can be quantified as a financial asset. This transition is <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Tj_59AWfKmWrcNIjgKv_IcQvml_wBRJCLCVZDxC-TidBIS-ypgAR7D3--3meCxuE34GXA30-avCMdLDXJSHg-g==" rel="nofollow" target="_blank">supported</a> by fair-value accounting principles under U.S. GAAP, which enable life sciences companies to http://www.streetinsider.com/Press+Releases/Advancing+Drug+Pipelines+Drive+Biotech+Valuations+as+Scientific+Progress+Gains+Financial+Recognition/26347871.html Wed, 22 Apr 2026 08:30:00 -0400 A.06822034 A.27822871 A.31293549 A.60012005 AUTL IOBTQ O.00222322 O.00573636 O.01670430 O.04698756 O.20026344 O.37399203 O.37872132 O.46180359 O.53121624 OTLC RHHBY RO WVE http://www.streetinsider.com/Press+Releases/Advancing+Drug+Pipelines+Drive+Biotech+Valuations+as+Scientific+Progress+Gains+Financial+Recognition/26347871.html <p>AUSTIN, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=fhktGMAc-YB8CA0Ov1Oayzf1xhnRI1_P2ocPmQDq0oZMFZs93VPW-0nX2AoZLMxpNsmGfNCCdHob5lRV2LFvT4_ZFAZd0THf1smoaVoIk6BRW86-qLxyaiHY_UvEA2--LWapUn5t-yI-Ujbf5eg3164eycLOmtE6il6mBvSmBjS2EAIxD0Rs8pPaV9FgoYe9IqNUeL0pAWfWEd5oFEk37InMLSR3xVidVCSAxDP9NNZ3Z-QsI5fVGiPPLFS1Kq_Vt_3IdFk9d3l50ZqYbIl6M-Ow5fNp_I9a-5QjUO6zhSaAZS55PJX9EodGQzpOehfq" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The biotechnology industry is experiencing a subtle yet meaningful transformation that is redefining how value is interpreted within a sector long associated with extended development cycles and inherent uncertainty. As therapeutic candidates advance toward commercialization, scientific achievement is no longer viewed purely as an expense tied to research and development but rather as something that can be quantified as a financial asset. This transition is <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Tj_59AWfKmWrcNIjgKv_IcQvml_wBRJCLCVZDxC-TidBIS-ypgAR7D3--3meCxuE34GXA30-avCMdLDXJSHg-g==" rel="nofollow" target="_blank">supported</a> by fair-value accounting principles under U.S. GAAP, which enable life sciences companies to http://www.streetinsider.com/Press+Releases/Advancing+Drug+Pipelines+Drive+Biotech+Valuations+as+Scientific+Progress+Gains+Financial+Recognition/26347871.html Wed, 22 Apr 2026 08:30:00 -0400 A.06822034 A.27822871 A.31293549 A.60012005 AUTL IOBTQ O.00222322 O.00573636 O.01670430 O.04698756 O.20026344 O.37399203 O.37872132 O.46180359 O.53121624 OTLC RHHBY RO WVE http://www.streetinsider.com/Press+Releases/Advancing+Drug+Pipelines+Drive+Biotech+Valuations+as+Scientific+Progress+Gains+Financial+Recognition/26347871.html <p>AUSTIN, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=fhktGMAc-YB8CA0Ov1Oayzf1xhnRI1_P2ocPmQDq0oZMFZs93VPW-0nX2AoZLMxpNsmGfNCCdHob5lRV2LFvT4_ZFAZd0THf1smoaVoIk6BRW86-qLxyaiHY_UvEA2--LWapUn5t-yI-Ujbf5eg3164eycLOmtE6il6mBvSmBjS2EAIxD0Rs8pPaV9FgoYe9IqNUeL0pAWfWEd5oFEk37InMLSR3xVidVCSAxDP9NNZ3Z-QsI5fVGiPPLFS1Kq_Vt_3IdFk9d3l50ZqYbIl6M-Ow5fNp_I9a-5QjUO6zhSaAZS55PJX9EodGQzpOehfq" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The biotechnology industry is experiencing a subtle yet meaningful transformation that is redefining how value is interpreted within a sector long associated with extended development cycles and inherent uncertainty. As therapeutic candidates advance toward commercialization, scientific achievement is no longer viewed purely as an expense tied to research and development but rather as something that can be quantified as a financial asset. This transition is <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Tj_59AWfKmWrcNIjgKv_IcQvml_wBRJCLCVZDxC-TidBIS-ypgAR7D3--3meCxuE34GXA30-avCMdLDXJSHg-g==" rel="nofollow" target="_blank">supported</a> by fair-value accounting principles under U.S. GAAP, which enable life sciences companies to http://www.streetinsider.com/Press+Releases/Advancing+Drug+Pipelines+Drive+Biotech+Valuations+as+Scientific+Progress+Gains+Financial+Recognition/26347871.html Wed, 22 Apr 2026 08:30:00 -0400 A.06822034 A.27822871 A.31293549 A.60012005 AUTL IOBTQ O.00222322 O.00573636 O.01670430 O.04698756 O.20026344 O.37399203 O.37872132 O.46180359 O.53121624 OTLC RHHBY RO WVE http://www.streetinsider.com/Press+Releases/Advancing+Drug+Pipelines+Drive+Biotech+Valuations+as+Scientific+Progress+Gains+Financial+Recognition/26347871.html <p>AUSTIN, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=fhktGMAc-YB8CA0Ov1Oayzf1xhnRI1_P2ocPmQDq0oZMFZs93VPW-0nX2AoZLMxpNsmGfNCCdHob5lRV2LFvT4_ZFAZd0THf1smoaVoIk6BRW86-qLxyaiHY_UvEA2--LWapUn5t-yI-Ujbf5eg3164eycLOmtE6il6mBvSmBjS2EAIxD0Rs8pPaV9FgoYe9IqNUeL0pAWfWEd5oFEk37InMLSR3xVidVCSAxDP9NNZ3Z-QsI5fVGiPPLFS1Kq_Vt_3IdFk9d3l50ZqYbIl6M-Ow5fNp_I9a-5QjUO6zhSaAZS55PJX9EodGQzpOehfq" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The biotechnology industry is experiencing a subtle yet meaningful transformation that is redefining how value is interpreted within a sector long associated with extended development cycles and inherent uncertainty. As therapeutic candidates advance toward commercialization, scientific achievement is no longer viewed purely as an expense tied to research and development but rather as something that can be quantified as a financial asset. This transition is <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Tj_59AWfKmWrcNIjgKv_IcQvml_wBRJCLCVZDxC-TidBIS-ypgAR7D3--3meCxuE34GXA30-avCMdLDXJSHg-g==" rel="nofollow" target="_blank">supported</a> by fair-value accounting principles under U.S. GAAP, which enable life sciences companies to http://www.streetinsider.com/Press+Releases/Advancing+Drug+Pipelines+Drive+Biotech+Valuations+as+Scientific+Progress+Gains+Financial+Recognition/26347871.html Wed, 22 Apr 2026 08:30:00 -0400 A.06822034 A.27822871 A.31293549 A.60012005 AUTL IOBTQ O.00222322 O.00573636 O.01670430 O.04698756 O.20026344 O.37399203 O.37872132 O.46180359 O.53121624 OTLC RHHBY RO WVE http://www.streetinsider.com/Press+Releases/Advancing+Drug+Pipelines+Drive+Biotech+Valuations+as+Scientific+Progress+Gains+Financial+Recognition/26347871.html <p>AUSTIN, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=fhktGMAc-YB8CA0Ov1Oayzf1xhnRI1_P2ocPmQDq0oZMFZs93VPW-0nX2AoZLMxpNsmGfNCCdHob5lRV2LFvT4_ZFAZd0THf1smoaVoIk6BRW86-qLxyaiHY_UvEA2--LWapUn5t-yI-Ujbf5eg3164eycLOmtE6il6mBvSmBjS2EAIxD0Rs8pPaV9FgoYe9IqNUeL0pAWfWEd5oFEk37InMLSR3xVidVCSAxDP9NNZ3Z-QsI5fVGiPPLFS1Kq_Vt_3IdFk9d3l50ZqYbIl6M-Ow5fNp_I9a-5QjUO6zhSaAZS55PJX9EodGQzpOehfq" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The biotechnology industry is experiencing a subtle yet meaningful transformation that is redefining how value is interpreted within a sector long associated with extended development cycles and inherent uncertainty. As therapeutic candidates advance toward commercialization, scientific achievement is no longer viewed purely as an expense tied to research and development but rather as something that can be quantified as a financial asset. This transition is <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Tj_59AWfKmWrcNIjgKv_IcQvml_wBRJCLCVZDxC-TidBIS-ypgAR7D3--3meCxuE34GXA30-avCMdLDXJSHg-g==" rel="nofollow" target="_blank">supported</a> by fair-value accounting principles under U.S. GAAP, which enable life sciences companies to http://www.streetinsider.com/Press+Releases/Advancing+Drug+Pipelines+Drive+Biotech+Valuations+as+Scientific+Progress+Gains+Financial+Recognition/26347871.html Wed, 22 Apr 2026 08:30:00 -0400 A.06822034 A.27822871 A.31293549 A.60012005 AUTL IOBTQ O.00222322 O.00573636 O.01670430 O.04698756 O.20026344 O.37399203 O.37872132 O.46180359 O.53121624 OTLC RHHBY RO WVE http://www.streetinsider.com/Press+Releases/Advancing+Drug+Pipelines+Drive+Biotech+Valuations+as+Scientific+Progress+Gains+Financial+Recognition/26347871.html <p>AUSTIN, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=fhktGMAc-YB8CA0Ov1Oayzf1xhnRI1_P2ocPmQDq0oZMFZs93VPW-0nX2AoZLMxpNsmGfNCCdHob5lRV2LFvT4_ZFAZd0THf1smoaVoIk6BRW86-qLxyaiHY_UvEA2--LWapUn5t-yI-Ujbf5eg3164eycLOmtE6il6mBvSmBjS2EAIxD0Rs8pPaV9FgoYe9IqNUeL0pAWfWEd5oFEk37InMLSR3xVidVCSAxDP9NNZ3Z-QsI5fVGiPPLFS1Kq_Vt_3IdFk9d3l50ZqYbIl6M-Ow5fNp_I9a-5QjUO6zhSaAZS55PJX9EodGQzpOehfq" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The biotechnology industry is experiencing a subtle yet meaningful transformation that is redefining how value is interpreted within a sector long associated with extended development cycles and inherent uncertainty. As therapeutic candidates advance toward commercialization, scientific achievement is no longer viewed purely as an expense tied to research and development but rather as something that can be quantified as a financial asset. This transition is <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Tj_59AWfKmWrcNIjgKv_IcQvml_wBRJCLCVZDxC-TidBIS-ypgAR7D3--3meCxuE34GXA30-avCMdLDXJSHg-g==" rel="nofollow" target="_blank">supported</a> by fair-value accounting principles under U.S. GAAP, which enable life sciences companies to http://www.streetinsider.com/Press+Releases/Advancing+Drug+Pipelines+Drive+Biotech+Valuations+as+Scientific+Progress+Gains+Financial+Recognition/26347871.html Wed, 22 Apr 2026 08:30:00 -0400 A.06822034 A.27822871 A.31293549 A.60012005 AUTL IOBTQ O.00222322 O.00573636 O.01670430 O.04698756 O.20026344 O.37399203 O.37872132 O.46180359 O.53121624 OTLC RHHBY RO WVE http://www.streetinsider.com/Press+Releases/Advancing+Drug+Pipelines+Drive+Biotech+Valuations+as+Scientific+Progress+Gains+Financial+Recognition/26347871.html <p>AUSTIN, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=fhktGMAc-YB8CA0Ov1Oayzf1xhnRI1_P2ocPmQDq0oZMFZs93VPW-0nX2AoZLMxpNsmGfNCCdHob5lRV2LFvT4_ZFAZd0THf1smoaVoIk6BRW86-qLxyaiHY_UvEA2--LWapUn5t-yI-Ujbf5eg3164eycLOmtE6il6mBvSmBjS2EAIxD0Rs8pPaV9FgoYe9IqNUeL0pAWfWEd5oFEk37InMLSR3xVidVCSAxDP9NNZ3Z-QsI5fVGiPPLFS1Kq_Vt_3IdFk9d3l50ZqYbIl6M-Ow5fNp_I9a-5QjUO6zhSaAZS55PJX9EodGQzpOehfq" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The biotechnology industry is experiencing a subtle yet meaningful transformation that is redefining how value is interpreted within a sector long associated with extended development cycles and inherent uncertainty. As therapeutic candidates advance toward commercialization, scientific achievement is no longer viewed purely as an expense tied to research and development but rather as something that can be quantified as a financial asset. This transition is <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Tj_59AWfKmWrcNIjgKv_IcQvml_wBRJCLCVZDxC-TidBIS-ypgAR7D3--3meCxuE34GXA30-avCMdLDXJSHg-g==" rel="nofollow" target="_blank">supported</a> by fair-value accounting principles under U.S. GAAP, which enable life sciences companies to http://www.streetinsider.com/Press+Releases/Advancing+Drug+Pipelines+Drive+Biotech+Valuations+as+Scientific+Progress+Gains+Financial+Recognition/26347871.html Wed, 22 Apr 2026 08:30:00 -0400 A.06822034 A.27822871 A.31293549 A.60012005 AUTL IOBTQ O.00222322 O.00573636 O.01670430 O.04698756 O.20026344 O.37399203 O.37872132 O.46180359 O.53121624 OTLC RHHBY RO WVE http://www.streetinsider.com/Press+Releases/Advancing+Drug+Pipelines+Drive+Biotech+Valuations+as+Scientific+Progress+Gains+Financial+Recognition/26347871.html <p>AUSTIN, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=fhktGMAc-YB8CA0Ov1Oayzf1xhnRI1_P2ocPmQDq0oZMFZs93VPW-0nX2AoZLMxpNsmGfNCCdHob5lRV2LFvT4_ZFAZd0THf1smoaVoIk6BRW86-qLxyaiHY_UvEA2--LWapUn5t-yI-Ujbf5eg3164eycLOmtE6il6mBvSmBjS2EAIxD0Rs8pPaV9FgoYe9IqNUeL0pAWfWEd5oFEk37InMLSR3xVidVCSAxDP9NNZ3Z-QsI5fVGiPPLFS1Kq_Vt_3IdFk9d3l50ZqYbIl6M-Ow5fNp_I9a-5QjUO6zhSaAZS55PJX9EodGQzpOehfq" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The biotechnology industry is experiencing a subtle yet meaningful transformation that is redefining how value is interpreted within a sector long associated with extended development cycles and inherent uncertainty. As therapeutic candidates advance toward commercialization, scientific achievement is no longer viewed purely as an expense tied to research and development but rather as something that can be quantified as a financial asset. This transition is <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Tj_59AWfKmWrcNIjgKv_IcQvml_wBRJCLCVZDxC-TidBIS-ypgAR7D3--3meCxuE34GXA30-avCMdLDXJSHg-g==" rel="nofollow" target="_blank">supported</a> by fair-value accounting principles under U.S. GAAP, which enable life sciences companies to http://www.streetinsider.com/Press+Releases/Advancing+Drug+Pipelines+Drive+Biotech+Valuations+as+Scientific+Progress+Gains+Financial+Recognition/26347871.html Wed, 22 Apr 2026 08:30:00 -0400 A.06822034 A.27822871 A.31293549 A.60012005 AUTL IOBTQ O.00222322 O.00573636 O.01670430 O.04698756 O.20026344 O.37399203 O.37872132 O.46180359 O.53121624 OTLC RHHBY RO WVE http://www.streetinsider.com/Press+Releases/Advancing+Drug+Pipelines+Drive+Biotech+Valuations+as+Scientific+Progress+Gains+Financial+Recognition/26347871.html <p>AUSTIN, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=fhktGMAc-YB8CA0Ov1Oayzf1xhnRI1_P2ocPmQDq0oZMFZs93VPW-0nX2AoZLMxpNsmGfNCCdHob5lRV2LFvT4_ZFAZd0THf1smoaVoIk6BRW86-qLxyaiHY_UvEA2--LWapUn5t-yI-Ujbf5eg3164eycLOmtE6il6mBvSmBjS2EAIxD0Rs8pPaV9FgoYe9IqNUeL0pAWfWEd5oFEk37InMLSR3xVidVCSAxDP9NNZ3Z-QsI5fVGiPPLFS1Kq_Vt_3IdFk9d3l50ZqYbIl6M-Ow5fNp_I9a-5QjUO6zhSaAZS55PJX9EodGQzpOehfq" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The biotechnology industry is experiencing a subtle yet meaningful transformation that is redefining how value is interpreted within a sector long associated with extended development cycles and inherent uncertainty. As therapeutic candidates advance toward commercialization, scientific achievement is no longer viewed purely as an expense tied to research and development but rather as something that can be quantified as a financial asset. This transition is <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Tj_59AWfKmWrcNIjgKv_IcQvml_wBRJCLCVZDxC-TidBIS-ypgAR7D3--3meCxuE34GXA30-avCMdLDXJSHg-g==" rel="nofollow" target="_blank">supported</a> by fair-value accounting principles under U.S. GAAP, which enable life sciences companies to http://www.streetinsider.com/Press+Releases/Advancing+Drug+Pipelines+Drive+Biotech+Valuations+as+Scientific+Progress+Gains+Financial+Recognition/26347871.html Wed, 22 Apr 2026 08:30:00 -0400 A.06822034 A.27822871 A.31293549 A.60012005 AUTL IOBTQ O.00222322 O.00573636 O.01670430 O.04698756 O.20026344 O.37399203 O.37872132 O.46180359 O.53121624 OTLC RHHBY RO WVE http://www.streetinsider.com/Press+Releases/Advancing+Drug+Pipelines+Drive+Biotech+Valuations+as+Scientific+Progress+Gains+Financial+Recognition/26347871.html <p>AUSTIN, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=fhktGMAc-YB8CA0Ov1Oayzf1xhnRI1_P2ocPmQDq0oZMFZs93VPW-0nX2AoZLMxpNsmGfNCCdHob5lRV2LFvT4_ZFAZd0THf1smoaVoIk6BRW86-qLxyaiHY_UvEA2--LWapUn5t-yI-Ujbf5eg3164eycLOmtE6il6mBvSmBjS2EAIxD0Rs8pPaV9FgoYe9IqNUeL0pAWfWEd5oFEk37InMLSR3xVidVCSAxDP9NNZ3Z-QsI5fVGiPPLFS1Kq_Vt_3IdFk9d3l50ZqYbIl6M-Ow5fNp_I9a-5QjUO6zhSaAZS55PJX9EodGQzpOehfq" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The biotechnology industry is experiencing a subtle yet meaningful transformation that is redefining how value is interpreted within a sector long associated with extended development cycles and inherent uncertainty. As therapeutic candidates advance toward commercialization, scientific achievement is no longer viewed purely as an expense tied to research and development but rather as something that can be quantified as a financial asset. This transition is <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Tj_59AWfKmWrcNIjgKv_IcQvml_wBRJCLCVZDxC-TidBIS-ypgAR7D3--3meCxuE34GXA30-avCMdLDXJSHg-g==" rel="nofollow" target="_blank">supported</a> by fair-value accounting principles under U.S. GAAP, which enable life sciences companies to http://www.streetinsider.com/Press+Releases/Advancing+Drug+Pipelines+Drive+Biotech+Valuations+as+Scientific+Progress+Gains+Financial+Recognition/26347871.html Wed, 22 Apr 2026 08:30:00 -0400 A.06822034 A.27822871 A.31293549 A.60012005 AUTL IOBTQ O.00222322 O.00573636 O.01670430 O.04698756 O.20026344 O.37399203 O.37872132 O.46180359 O.53121624 OTLC RHHBY RO WVE http://www.streetinsider.com/Press+Releases/Advancing+Drug+Pipelines+Drive+Biotech+Valuations+as+Scientific+Progress+Gains+Financial+Recognition/26347871.html <p>AUSTIN, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=fhktGMAc-YB8CA0Ov1Oayzf1xhnRI1_P2ocPmQDq0oZMFZs93VPW-0nX2AoZLMxpNsmGfNCCdHob5lRV2LFvT4_ZFAZd0THf1smoaVoIk6BRW86-qLxyaiHY_UvEA2--LWapUn5t-yI-Ujbf5eg3164eycLOmtE6il6mBvSmBjS2EAIxD0Rs8pPaV9FgoYe9IqNUeL0pAWfWEd5oFEk37InMLSR3xVidVCSAxDP9NNZ3Z-QsI5fVGiPPLFS1Kq_Vt_3IdFk9d3l50ZqYbIl6M-Ow5fNp_I9a-5QjUO6zhSaAZS55PJX9EodGQzpOehfq" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The biotechnology industry is experiencing a subtle yet meaningful transformation that is redefining how value is interpreted within a sector long associated with extended development cycles and inherent uncertainty. As therapeutic candidates advance toward commercialization, scientific achievement is no longer viewed purely as an expense tied to research and development but rather as something that can be quantified as a financial asset. This transition is <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Tj_59AWfKmWrcNIjgKv_IcQvml_wBRJCLCVZDxC-TidBIS-ypgAR7D3--3meCxuE34GXA30-avCMdLDXJSHg-g==" rel="nofollow" target="_blank">supported</a> by fair-value accounting principles under U.S. GAAP, which enable life sciences companies to http://www.streetinsider.com/Press+Releases/Advancing+Drug+Pipelines+Drive+Biotech+Valuations+as+Scientific+Progress+Gains+Financial+Recognition/26347871.html Wed, 22 Apr 2026 08:30:00 -0400 A.06822034 A.27822871 A.31293549 A.60012005 AUTL IOBTQ O.00222322 O.00573636 O.01670430 O.04698756 O.20026344 O.37399203 O.37872132 O.46180359 O.53121624 OTLC RHHBY RO WVE http://www.streetinsider.com/Press+Releases/Advancing+Drug+Pipelines+Drive+Biotech+Valuations+as+Scientific+Progress+Gains+Financial+Recognition/26347871.html <p>AUSTIN, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=fhktGMAc-YB8CA0Ov1Oayzf1xhnRI1_P2ocPmQDq0oZMFZs93VPW-0nX2AoZLMxpNsmGfNCCdHob5lRV2LFvT4_ZFAZd0THf1smoaVoIk6BRW86-qLxyaiHY_UvEA2--LWapUn5t-yI-Ujbf5eg3164eycLOmtE6il6mBvSmBjS2EAIxD0Rs8pPaV9FgoYe9IqNUeL0pAWfWEd5oFEk37InMLSR3xVidVCSAxDP9NNZ3Z-QsI5fVGiPPLFS1Kq_Vt_3IdFk9d3l50ZqYbIl6M-Ow5fNp_I9a-5QjUO6zhSaAZS55PJX9EodGQzpOehfq" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The biotechnology industry is experiencing a subtle yet meaningful transformation that is redefining how value is interpreted within a sector long associated with extended development cycles and inherent uncertainty. As therapeutic candidates advance toward commercialization, scientific achievement is no longer viewed purely as an expense tied to research and development but rather as something that can be quantified as a financial asset. This transition is <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Tj_59AWfKmWrcNIjgKv_IcQvml_wBRJCLCVZDxC-TidBIS-ypgAR7D3--3meCxuE34GXA30-avCMdLDXJSHg-g==" rel="nofollow" target="_blank">supported</a> by fair-value accounting principles under U.S. GAAP, which enable life sciences companies to http://www.streetinsider.com/Press+Releases/Advancing+Drug+Pipelines+Drive+Biotech+Valuations+as+Scientific+Progress+Gains+Financial+Recognition/26347871.html Wed, 22 Apr 2026 08:30:00 -0400 A.06822034 A.27822871 A.31293549 A.60012005 AUTL IOBTQ O.00222322 O.00573636 O.01670430 O.04698756 O.20026344 O.37399203 O.37872132 O.46180359 O.53121624 OTLC RHHBY RO WVE http://www.streetinsider.com/Press+Releases/Advancing+Drug+Pipelines+Drive+Biotech+Valuations+as+Scientific+Progress+Gains+Financial+Recognition/26347871.html <p>AUSTIN, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=fhktGMAc-YB8CA0Ov1Oayzf1xhnRI1_P2ocPmQDq0oZMFZs93VPW-0nX2AoZLMxpNsmGfNCCdHob5lRV2LFvT4_ZFAZd0THf1smoaVoIk6BRW86-qLxyaiHY_UvEA2--LWapUn5t-yI-Ujbf5eg3164eycLOmtE6il6mBvSmBjS2EAIxD0Rs8pPaV9FgoYe9IqNUeL0pAWfWEd5oFEk37InMLSR3xVidVCSAxDP9NNZ3Z-QsI5fVGiPPLFS1Kq_Vt_3IdFk9d3l50ZqYbIl6M-Ow5fNp_I9a-5QjUO6zhSaAZS55PJX9EodGQzpOehfq" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The biotechnology industry is experiencing a subtle yet meaningful transformation that is redefining how value is interpreted within a sector long associated with extended development cycles and inherent uncertainty. As therapeutic candidates advance toward commercialization, scientific achievement is no longer viewed purely as an expense tied to research and development but rather as something that can be quantified as a financial asset. This transition is <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Tj_59AWfKmWrcNIjgKv_IcQvml_wBRJCLCVZDxC-TidBIS-ypgAR7D3--3meCxuE34GXA30-avCMdLDXJSHg-g==" rel="nofollow" target="_blank">supported</a> by fair-value accounting principles under U.S. GAAP, which enable life sciences companies to http://www.streetinsider.com/Press+Releases/Advancing+Drug+Pipelines+Drive+Biotech+Valuations+as+Scientific+Progress+Gains+Financial+Recognition/26347871.html Wed, 22 Apr 2026 08:30:00 -0400 A.06822034 A.27822871 A.31293549 A.60012005 AUTL IOBTQ O.00222322 O.00573636 O.01670430 O.04698756 O.20026344 O.37399203 O.37872132 O.46180359 O.53121624 OTLC RHHBY RO WVE http://www.streetinsider.com/Press+Releases/Advancing+Drug+Pipelines+Drive+Biotech+Valuations+as+Scientific+Progress+Gains+Financial+Recognition/26347871.html <p>AUSTIN, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=fhktGMAc-YB8CA0Ov1Oayzf1xhnRI1_P2ocPmQDq0oZMFZs93VPW-0nX2AoZLMxpNsmGfNCCdHob5lRV2LFvT4_ZFAZd0THf1smoaVoIk6BRW86-qLxyaiHY_UvEA2--LWapUn5t-yI-Ujbf5eg3164eycLOmtE6il6mBvSmBjS2EAIxD0Rs8pPaV9FgoYe9IqNUeL0pAWfWEd5oFEk37InMLSR3xVidVCSAxDP9NNZ3Z-QsI5fVGiPPLFS1Kq_Vt_3IdFk9d3l50ZqYbIl6M-Ow5fNp_I9a-5QjUO6zhSaAZS55PJX9EodGQzpOehfq" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The biotechnology industry is experiencing a subtle yet meaningful transformation that is redefining how value is interpreted within a sector long associated with extended development cycles and inherent uncertainty. As therapeutic candidates advance toward commercialization, scientific achievement is no longer viewed purely as an expense tied to research and development but rather as something that can be quantified as a financial asset. This transition is <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Tj_59AWfKmWrcNIjgKv_IcQvml_wBRJCLCVZDxC-TidBIS-ypgAR7D3--3meCxuE34GXA30-avCMdLDXJSHg-g==" rel="nofollow" target="_blank">supported</a> by fair-value accounting principles under U.S. GAAP, which enable life sciences companies to http://www.streetinsider.com/Press+Releases/Advancing+Drug+Pipelines+Drive+Biotech+Valuations+as+Scientific+Progress+Gains+Financial+Recognition/26347871.html Wed, 22 Apr 2026 08:30:00 -0400 A.06822034 A.27822871 A.31293549 A.60012005 AUTL IOBTQ O.00222322 O.00573636 O.01670430 O.04698756 O.20026344 O.37399203 O.37872132 O.46180359 O.53121624 OTLC RHHBY RO WVE http://www.streetinsider.com/Press+Releases/Advancing+Drug+Pipelines+Drive+Biotech+Valuations+as+Scientific+Progress+Gains+Financial+Recognition/26347871.html <p>AUSTIN, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=fhktGMAc-YB8CA0Ov1Oayzf1xhnRI1_P2ocPmQDq0oZMFZs93VPW-0nX2AoZLMxpNsmGfNCCdHob5lRV2LFvT4_ZFAZd0THf1smoaVoIk6BRW86-qLxyaiHY_UvEA2--LWapUn5t-yI-Ujbf5eg3164eycLOmtE6il6mBvSmBjS2EAIxD0Rs8pPaV9FgoYe9IqNUeL0pAWfWEd5oFEk37InMLSR3xVidVCSAxDP9NNZ3Z-QsI5fVGiPPLFS1Kq_Vt_3IdFk9d3l50ZqYbIl6M-Ow5fNp_I9a-5QjUO6zhSaAZS55PJX9EodGQzpOehfq" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The biotechnology industry is experiencing a subtle yet meaningful transformation that is redefining how value is interpreted within a sector long associated with extended development cycles and inherent uncertainty. As therapeutic candidates advance toward commercialization, scientific achievement is no longer viewed purely as an expense tied to research and development but rather as something that can be quantified as a financial asset. This transition is <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Tj_59AWfKmWrcNIjgKv_IcQvml_wBRJCLCVZDxC-TidBIS-ypgAR7D3--3meCxuE34GXA30-avCMdLDXJSHg-g==" rel="nofollow" target="_blank">supported</a> by fair-value accounting principles under U.S. GAAP, which enable life sciences companies to http://www.streetinsider.com/Press+Releases/Advancing+Drug+Pipelines+Drive+Biotech+Valuations+as+Scientific+Progress+Gains+Financial+Recognition/26347871.html Wed, 22 Apr 2026 08:30:00 -0400 A.06822034 A.27822871 A.31293549 A.60012005 AUTL IOBTQ O.00222322 O.00573636 O.01670430 O.04698756 O.20026344 O.37399203 O.37872132 O.46180359 O.53121624 OTLC RHHBY RO WVE http://www.streetinsider.com/Press+Releases/Advancing+Drug+Pipelines+Drive+Biotech+Valuations+as+Scientific+Progress+Gains+Financial+Recognition/26347871.html <p>AUSTIN, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=fhktGMAc-YB8CA0Ov1Oayzf1xhnRI1_P2ocPmQDq0oZMFZs93VPW-0nX2AoZLMxpNsmGfNCCdHob5lRV2LFvT4_ZFAZd0THf1smoaVoIk6BRW86-qLxyaiHY_UvEA2--LWapUn5t-yI-Ujbf5eg3164eycLOmtE6il6mBvSmBjS2EAIxD0Rs8pPaV9FgoYe9IqNUeL0pAWfWEd5oFEk37InMLSR3xVidVCSAxDP9NNZ3Z-QsI5fVGiPPLFS1Kq_Vt_3IdFk9d3l50ZqYbIl6M-Ow5fNp_I9a-5QjUO6zhSaAZS55PJX9EodGQzpOehfq" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: The biotechnology industry is experiencing a subtle yet meaningful transformation that is redefining how value is interpreted within a sector long associated with extended development cycles and inherent uncertainty. As therapeutic candidates advance toward commercialization, scientific achievement is no longer viewed purely as an expense tied to research and development but rather as something that can be quantified as a financial asset. This transition is <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Tj_59AWfKmWrcNIjgKv_IcQvml_wBRJCLCVZDxC-TidBIS-ypgAR7D3--3meCxuE34GXA30-avCMdLDXJSHg-g==" rel="nofollow" target="_blank">supported</a> by fair-value accounting principles under U.S. GAAP, which enable life sciences companies to http://www.streetinsider.com/Press+Releases/Advancing+Drug+Pipelines+Drive+Biotech+Valuations+as+Scientific+Progress+Gains+Financial+Recognition/26347871.html Wed, 22 Apr 2026 08:30:00 -0400 A.06822034 A.27822871 A.31293549 A.60012005 AUTL IOBTQ O.00222322 O.00573636 O.01670430 O.04698756 O.20026344 O.37399203 O.37872132 O.46180359 O.53121624 OTLC RHHBY RO WVE